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Abstract
Background: Breast cancer is the most prevalent cancer among women. Biomarkers that are expressed in tumors play a pivotal
role in diagnosis and treatment. Cancer-testis (CT) antigens are predominantly expressed in the testis and also have inappropriate
expression in various tumor types. In the case of expression in tumors, they will be used as immunotherapy targets.
Objectives: Expression of ARMC3, a CT antigen, was analyzed to determine its potential as a tumor marker for breast cancer.
Materials and Methods: Eighty samples including 40 tumor samples and 40 normal adjacent tissue samples, were gathered from
the ICBC biobank. RNA extraction was carried out on all samples. The extracted RNA was treated by DNaseI, after which cDNA was
synthesized. Expression of ARMC3 with ACTB (internal control) was studied using Real-Time PCR (polymerase chain reaction).
Results: Overall, 43.6% of tumors and 25.6% of normal adjacent tissues expressed ARMC3. ARMC3 was overexpressed in 41% of tumor
samples (P = 0.00) and showed decreased expression in 46.2% (P = 0.00). Also, the expression of this gene in 12.8% of tumors was
unchanged, which was statistically significant. It should be noted that all samples expressed ACTB gene.
Conclusions: Expression of ARMC3 in tumor samples and normal adjacent tissue is very important. The expression of this gene
in tumor-adjacent tissue may be associated with the stage of cancer; it may be that these tissues are affected by epigenetic and
oncogenic changes of breast cancer. Accordingly, aberrant expression of ARMC3 in tumor samples may be an attractive candidate
for use as a tumor marker.
Keywords: Breast Cancer, Cancer-Testis Genes, Biomarker
1. Background
Breast cancer (BC) is viewed as the most frequent type
of malignancy, accounting for 22% of all cancers diagnosed
in women. BC is a heterogeneous and complex disease with
distinct pathologies and specific histological features. In
Iran, BC ranks first among cancers diagnosed in women,
making up 24.4% of all malignancies. BC is characterized
by the proliferation and abnormal differentiation of ma-
lignant immature cells that often carry aberrations that
deregulate hundreds or even thousands of genes (1-5).
Cancer-testis (CT) antigens are named for their typical
pattern of expressions as they are present in a significant
subset of malignant tumors, whereas their expression in
other tissues is limited (6-9). CT antigens were discovered
in 1991 by van der Bruggen et al. when the first tumorous
antigen was determined to significantly alter the immuno-
logic response of tumors (10). In various clinical trials, sev-
eral CT antigens have been successfully employed as target
antigens (11-13). Aberrant CT antigen expression in cancer
has been reported in previous studies, including studies
on breast cancer (14).
There are now more than 100 gene families (such as
ARMC3) that have been determined to be up-regulated in
cancer; however, their biological function remains unclear
(15, 16). The armadillo (ARM) is a repeating protein related
to the Drosophila melanogaster armadillo protein, a pro-
tein essential for Wingless signal transduction. ARMC3 (ar-
madillo repeat-containing protein 3), also known as the β-
catenin-like protein, belongs to the CT81 family and is lo-
cated at 10p12.31. ARMC3 encodes an 872-amino-acid pro-
tein that contains 12 ARM domains. ARM proteins are in-
volved in a variety of processes such as cell migration,
cell proliferation, tissue maintenance, and tumorigene-
sis. They are intracellular proteins that function in signal
transduction and cell structure. ARMC3 has been identi-
fied in many cancer tissues and is thought to play a role
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in tumor initiation. Some data has been published regard-
ing ARMC3 mRNA expression in neoplasias such as colon
and lung carcinoma and endometrial cancer (17, 18). The
expression of several CT antigens has been analyzed in a va-
riety of malignant neoplasms on an mRNA level (18).
The function of ARMC3 in breast cancer remains un-
clear. Therefore, further investigations are necessary to
determine the functional role of ARMC3 in the formation
of malignant phenotype cancer cells and cancer develop-
ment.
2. Objectives
In order to analyze these CT antigens, we launched an
investigation on the expression of ARMC3 a testis-specific
gene, at the mRNA level, in a series of 80 breast tissue sam-
ples by quantitative real-time PCR (q-RT-PCR).
3. Materials and Methods
3.1. Study Population
Samples were obtained from the breast cancer re-
search center Biobank (BCRC-BB) (19). The study protocol
was approved by the ethics committee of Qazvin University
of medical Science, in compliance with the Helsinki dec-
laration. The BCRC–BB should observe ethical guidelines
and recommendations for Biobanks on the storage and use
of human biological samples. Two types of tissues, includ-
ing invasive ductal carcinoma and normal adjacent tissue
were obtained from BCRC-BB. Five human testis tissue sam-
ples were provided by the Royan institute as the positive
control.
3.2. Sample Preparation
Tissues were cut into pieces on dry ice (8 - 20 mg)
and homogenized in 1 mL of RNX-Plus (Cinnagen, Iran)
to extract RNA, according to the manufacturer’s proto-
col. Extracted RNA was checked qualitatively and quanti-
tatively by gel electrophoresis and spectrophotometry, re-
spectively. In order to verify the quality of extracted RNA
samples, electrophoresis was carried out on 1% agarose.
Then 28s and 18s ribosomal bands, as well as contamina-
tion of DNA, were assessed. The RNA was quantified by a
spectrophotometer at 260 nm (Biochrom WPA Biowave II).
Extracted RNA was treated with RNase-free DNase I (Takara)
to prevent the proliferation of genomic DNA contamina-
tion. Next, cDNA was synthesized using a QuantiTect re-
verse transcription kit (Qiagen).
All primers and probes were designed using primer
express V.3.0 software (applied biosystems). To check the
sequence specificity and avoid any homology to other
parts of the human genome, all sequences were verified at
http://www.ncbi.nlm.nih.gov/BLAST/.
In order to achieve PCR efficiency, serial dilutions were
performed using pooled cDNA from five testis cDNAs with
equal proportions, then amplification efficiency for each
primer was approximated by using four-fold cDNA serial
dilutions and calculated using 7500 software system ver.
2.0. The sequences and final concentration of primers and
probes are listed in Table 1.
Q-RT-PCR was carried out in triplicate using Precision
2 × qPCR Mastermix (PrimerDesign Ltd, UK) in 15 µL reac-
tions. The two-step real-time PCR protocol was used. Cy-
cle profiles of real-time PCR were as follows: activation of
polymerase at 95°C for 10 minutes, and 40 cycles of ampli-
fication (95°C for 15 seconds, 60°C for 30 seconds). The flu-
orescence was measured using applied bio-systems 7500
real-time PCR system. After reviewing the initial data, in-
cluding the results of the amplified samples, threshold cy-
cles (Ct) were collected. To determine the expression of tar-
get genes in tumor and normal adjacent tissue, normaliza-
tion of each sample result was performed by subtracting
the Ct for the target gene from the housekeeping gene Ct
(β-actin) using the 2-∆∆CT formula.
3.3. Statistical Analysis
Final relative gene expression data were analyzed us-
ing REST 2009 software. Descriptive and analytical analy-
ses of data were carried out using SPSS software version 18.
4. Results
The mean age of patients with BC was 49.16± 1.713 years
(range 29 - 74 years). Fifty percent of cases were estrogen-
receptor (ER) positive and 58.7% were ER negative. Demo-
graphic data are summarized in Table 2.
The mean quantity of RNA measured by the spec-
trophotometer at 260 nm was 1.15 ± 0.30 µg µL-1. Accord-
ing to the descriptive analysis, ARMC3 was expressed in
43.6% of breast tumor samples and 25.6% of normal adja-
cent tissue samples. ARMC3 was overexpressed in 41% of
the tumor samples (P = 0.00) and showed decreased ex-
pression in 46.2% of the tumor samples (p = 0.00). The ex-
pression of this gene in 12.8% of tumors did not undergo
change, which was statistically significant.
In normal testis samples, the highest levels of tran-
script were observed in comparison to breast tumor and
adjacent samples (P = 0.00).
After normalization of the expression levels using β-
actin (ACTB) as internal reference, no significant changes
were observed in the expression of ARMC3 in breast cancer
tumors in comparison to normal adjacent breast tissue.
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Table 1. Information for the Studied Genes
Gene Primer PCR Product Length, bp PCR Efficiency, % Optimum Concentration,µM
ARMC3 138 97 0.3
Forward 5’-GCAACGAGGCACAACAAGG-3’
Reverse 5’-GGTCAAACACATCCTTAGGAGG-3’
Probe 5’-CCTTCTTTATCTTTTTACCCATCCTGCCGG-3’
ACTB 66 95 0.5
Forward 5’-CAGCAGATGTGGATCAGCAAG-3’
Reverse 5’-GCATTTGCGGTGGACGAT-3’
Probe 5’-AGGAGTATGACGAGTCCGGCCCC-3’
Table 2. Selected Characteristics of Breast Cancer Subjectsa
Characteristics Percent
Ageb 49.16 (1.713)
Stage
I 11.6
II 45.6
III 28.8
IV 13.8
Grade
I 12.2
II 51.2
III 36.6
ER/PR
ER/PR positive 50/41.3
ER/PR negative 50/58.7
HER-2
Positive 41.3
Negative 58.7
aN = 80.
bValues are expressed as mean (SD).
The ARMC3 expression ratio was 0.770 (SD: 0.011 - 40.966;
95% CI: 0.000 - 11,275.530; P = 0.750).
5. Discussion
Although great strides have been taken in the treat-
ment of cancer, breast cancer still accounts for severe
cancer mortality among women. Considering this situa-
tion, finding biomarkers expressed in cancer would be a
promising method for diagnosing and treating it. The first
step for this purpose would be identifying biomarkers that
are extensively expressed in various stages of cancer pro-
gression, especially the initial stages (2).
Cancer-testis genes express a number of immunologic
proteins often exclusively expressed in normal testis tis-
sues and some tumors. These antigens are proteins that
are naturally expressed in male generative cells. There is
evidence for the functional roles of CT antigens, includ-
ing modulating gene expression and contributing to tu-
mor signaling pathways, tumor cell division, and apopto-
sis (20). Due to the tissue-exclusivity and immunogenic-
ity of the cancer-testis antigens, and their infrequent ex-
pression in normal tissues, one could construe their ex-
pression in tumorous tissues as a cancer biomarker. Unlike
chemotherapy and radiotherapy, which kill healthy divid-
ing cells in addition to tumor cells, CT antigens can be used
for specific targeting of cancer cells using immunother-
apy (21). Many CT antigens form the basis for peptide-
based CT cancer vaccine trials (22), and phase 1 studies uti-
lizing different types of these vaccines for a number of
malignancies have identified these methods as harmless
(23). The humoral immune response to CT antigens has
been observed in numerous tumors, for instance antibod-
ies against ARMC3 were identified in pancreatic, prostate,
and endometrial cancers (18, 24).
There is a list of several known CT genes in breast can-
cer (25). Overexpression of some CT antigens in breast tu-
mors (26) and a combination of different tumors was pre-
viously reported (27).
Armadillo/β-catenin (ARM) domains are imperfect 45-
amino acid repeats that are involved in protein–protein
interactions. ARM domain-containing proteins, such as
ARMC3, are active in signal transduction, development,
cell adhesion and mobility, and tumor initiation and
metastasis (17).
In a study using the RT-PCR method in 2006, the ARMC3
expression at the mRNA level was reported at 33% and 38%
for pancreatic and lung cancers, respectively (18). In the
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present study, research on ARMC3 expression at the mRNA
level showed that ARMC3 was expressed in 43.6% of tumors
and 25.6% of normal adjacent tissues. ARMC3 expression
increased in 41% and decreased in 46.2% of the tumor sam-
ples. The expression was not changed in 12.8% of the tumor
samples, meaning tumorous and normal adjacent tissues
had similar expressions.
The results of this study showed very low levels of
ARMC3 transcripts in the breast tissue samples, whereas
the highest levels of transcript were observed in normal
testis with highly significant differences in the gene ex-
pression ratio in comparison with breast tissue samples,
confirming the restricted expression pattern of the genes
in normal testis.
There have not been sufficient studies on ARMC3, and
the clinical significance of ARMC3, especially in human
breast cancer, remains to be the subject of future research.
The expression of these genes in normal tissues adja-
cent to tumors could be related to the concretization stage.
The glandular epithelial cells in the breast undergo cycli-
cal proliferation, which favors neoplastic transformation,
and could be attributed to genomic instability in normal
breast lobules adjacent to the cancer focus (28). The ex-
pression of these genes in the adjacent tissues could there-
fore be caused by epigenetic and oncogenic changes in the
breast cancer and point to biomarkers of vital importance.
The reason behind conflicting reports about the ex-
pression of these genes in tumors has not yet been iden-
tified. It may be due to varying genetic reserves of dif-
ferent populations being studied, or it could result from
technical or sample volume discrepancies. The majority of
studies mentioned were conducted on limited numbers of
samples. It must be noted that tumorous samples in dif-
ferent studies are provided from various stages of cancer.
This heterogeneity can influence the obtained results. The
effect of genetic heterogeneity in cancers also needs to be
considered, as well as the discrepancies inherent in the def-
inition and diagnosis of progression stages of breast can-
cer in this respect (29, 30).
It is proposed that ARMC3 expression in breast cancer
cell lines should also be considered, and the relation be-
tween ARMC3 expression and the clinicopathological char-
acteristics of the disease should be assessed and compared
to obtain further information about the genetic correla-
tion and prognosis of breast cancer. In the next stages of
the research, it is recommended that the generation and
expression of antibodies against ARMC3 in the serum be
considered. It is hoped that these cancer-testis antigens
such as ARMC3 can be employed to advance immunother-
apy of breast cancer, in that ARMC3 is expressed in the pro-
tein level and is immunogenic.
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